Ionis Priority Review and enrollment in Phase 3 program

  Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome –

–         Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 –

https://www.prnewswire.com/news-releases/ionis-announces-olezarsen-fcs-new-drug-application-accepted-for-priority-review-and-enrollment-in-phase-3-shtg-program-completed-302181549.html